Prevention of coronary heart disease by raising high-density lipoprotein cholesterol?
Consistent with several potentially anti-atherogenic activities of high-density lipoproteins in vitro, low plasma levels of high-density lipoprotein cholesterol are associated with an increased risk of coronary heart disease. In addition to genes, lifestyle factors (e.g. smoking, being overweight and physical inactivity) strongly affect plasma high-density lipoprotein cholesterol levels. Moreover, a low level of high-density lipoprotein cholesterol interacts with other risk factors. Raising of high-density lipoprotein cholesterol by either adjustments of lifestyle or drug intervention as well as elimination of additional risk factors are thus thought to affect coronary risk. Here, we summarize the outcomes of observational and interventional studies as well as genetic and experimental research which have recently much advanced our understanding of the function and regulation of high-density lipoprotein metabolism. We conclude from the data that changes in the kinetics and functionality of high-density lipoprotein rather than changes in plasma high-density lipoprotein cholesterol levels per se will affect the anti-atherogenicity of therapeutic interference with high-density lipoprotein metabolism.
von Eckardstein
A
A
Institut für Klinische Chemie und Laboratoriumsmedizin, Zentrallaboratorium, Westfälische Wilhelms-Universität Münster, Germany. vonecka@uni-muenster.de
Assmann
G
G
D000328:Adult; D000368:Aged; D000465:Algorithms; D000818:Animals; D015992:Body Mass Index; D008076:Cholesterol, HDL / Q000097:blood / Q000378:metabolism*; D003327:Coronary Disease / Q000517:prevention & control*; D004967:Estrogens / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D009525:Niacin / Q000627:therapeutic use; D012306:Risk
D008076:Cholesterol, HDL; D004967:Estrogens; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D009525:Niacin